Scarica l'app Stockscreener
20.81
3.84%
-0.83
Dopo l'orario di chiusura:
20.52
-0.29
-1.39%
Precedente Chiudi:
$21.64
Aprire:
$21.02
Volume 24 ore:
1.62M
Relative Volume:
0.66
Capitalizzazione di mercato:
$2.66B
Reddito:
$631.73M
Utile/perdita netta:
$-239.78M
Rapporto P/E:
-10.30
EPS:
-2.02
Flusso di cassa netto:
$-33.45M
1 W Prestazione:
-9.72%
1M Prestazione:
+11.82%
6M Prestazione:
+49.07%
1 anno Prestazione:
+81.43%
Intervallo 1D:
$20.57
$21.43
Intervallo di 1 settimana:
$20.57
$23.30
Portata 52W:
$6.78
$23.56
10 X Genomics Inc Stock (TXG) Company Profile
Nome
10 X Genomics Inc
Settore
Industria
Telefono
(925) 401-7300
Indirizzo
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, TEM, BTSG, HQY, WAY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
20.81 | 2.76B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
195.49 | 32.23B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
52.26 | 9.48B | 1.27B | -245.03M | -245.36M | -1.4071 |
|
BTSG
Brightspring Health Services Inc
|
41.49 | 8.08B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
78.36 | 6.83B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
25.71 | 5.09B | 906.14M | -52.62M | 89.62M | -0.3621 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2025-12-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | Iniziato | Piper Sandler | Neutral |
| 2025-02-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Iniziato | Leerink Partners | Outperform |
| 2024-07-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-07-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-05-01 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-10 | Iniziato | Barclays | Overweight |
| 2023-03-31 | Iniziato | Stephens | Overweight |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-08-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-07-25 | Iniziato | Canaccord Genuity | Buy |
| 2022-07-15 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-14 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-15 | Iniziato | William Blair | Outperform |
| 2020-12-02 | Iniziato | Goldman | Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-10 | Iniziato | Stifel | Buy |
| 2020-03-05 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-07 | Iniziato | BofA/Merrill | Buy |
| 2019-10-07 | Iniziato | Cowen | Outperform |
| 2019-10-07 | Iniziato | JP Morgan | Overweight |
| 2019-09-24 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
10 X Genomics Inc Borsa (TXG) Ultime notizie
Citigroup Inc. Increases Holdings in 10x Genomics $TXG - MarketBeat
ARK Investment Cuts Stake in 10x Genomics - National Today
10x genomics CEO Saxonov sells $367,096 in shares - Investing.com UK
10x Genomics (TXG) CEO sells shares and makes stock gift - Stock Titan
10x Genomics $TXG Position Lifted by Vanguard Group Inc. - MarketBeat
10X Genomics Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Breaking Down 10x Genomics: 11 Analysts Share Their Views - Sahm
Commit To Buy 10x Genomics At $15, Earn 20.6% Annualized Using Options - Nasdaq
TXG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
10x Genomics, Inc. (TXG) Stock Analysis: A Closer Look at the Healthcare Innovator’s Growth Potential and Analyst Ratings - DirectorsTalk Interviews
Stifel Nicolaus Boosts 10x Genomics Price Target to $25 - National Today
Major RSU grant to 10x Genomics (TXG) CEO Serge Saxonov - Stock Titan
88,816 RSUs awarded to 10x Genomics (TXG) director Hindson - Stock Titan
10x Genomics (TXG) CFO granted 106,579 RSUs in new equity award - Stock Titan
TXG affiliate files Form 144: proposed Class A Common sale (NASDAQ: TXG) - Stock Titan
10X Genomics Hits Day High with Strong 12.56% Intraday Surge - Markets Mojo
10x Genomics (NASDAQ:TXG) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Is It Time To Reassess 10x Genomics (TXG) After Its 1 Year Share Price Surge - Yahoo Finance
10x Genomics (NASDAQ:TXG) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Is 10x Genomics Inc.’s ROIC above industry averageTrade Performance Summary & AI Driven Price Forecasts - mfd.ru
Insider Sell: Sarah Teichmann Sells Shares of 10x Genomics Inc (TXG) - GuruFocus
Director at 10x Genomics (TXG) sells 7,579 shares under 10b5-1 plan - Stock Titan
10x Genomics (TXG) Price Target Increased by 10.28% to 20.33 - Nasdaq
10x Genomics (NASDAQ:TXG) CEO Serge Saxonov Sells 9,632 Shares of Stock - MarketBeat
10x Genomics (TXG) CEO sells 9,632 shares to cover RSU tax - Stock Titan
[Form 4] 10x Genomics, Inc. Insider Trading Activity - Stock Titan
10x Genomics (TXG) officer sells 7,826 shares to cover RSU tax - Stock Titan
10x Genomics, Inc. (TXG) Stock Analysis: Navigating Growth Potential In Health Information Services - DirectorsTalk Interviews
Vestmark Advisory Solutions Inc. Sells 340,854 Shares of 10x Genomics $TXG - MarketBeat
Insider sale filing for TXG (NASDAQ: TXG) lists 8,301 shares on 02/23/2026 - Stock Titan
TXG (NASDAQ: TXG) insider sale notice: 25,784 RSU shares listed for sale - Stock Titan
Issuer insider sale notice — 23,767 shares (NASDAQ: TXG) - Stock Titan
Is 10x Genomics Inc. (1KJ) stock positioned for secular growthRecession Risk & Expert Curated Trade Ideas - mfd.ru
TXG: UBS Raises Price Target for 10x Genomics to $20 | TXG Stock News - GuruFocus
10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference - BioSpace
5 Must-Read Analyst Questions From 10x Genomics's Q4 Earnings Call - Finviz
GSA Capital Partners LLP Buys 106,167 Shares of 10x Genomics $TXG - MarketBeat
162,202 Shares in 10x Genomics $TXG Bought by Principal Financial Group Inc. - MarketBeat
10x Genomics Stock Climbs as Analysts Signal Growth Prospects - StocksToTrade
10x Genomics’ Growth Prospects Brightened by Strategic Advances - timothysykes.com
10x Genomics Cancer Alliances Test AI Ambitions Against Mixed Share Performance - Yahoo Finance
10x Genomics Sees Bullish Momentum Following Revenue Projections and Price Target Upgrades - StocksToTrade
10x Genomics Sees Bullish Momentum with Raised Price Targets - timothysykes.com
Is 10x Genomics Inc. still a buy after recent gains2025 Biggest Moves & AI Forecast Swing Trade Picks - mfd.ru
Decoding 10x Genomics Inc (TXG): A Strategic SWOT Insight - GuruFocus
Earnings Call Summary | 10x Genomics(TXG.US) Q4 2025 Earnings Conference - 富途牛牛
Expert Outlook: 10x Genomics Through The Eyes Of 10 Analysts - Benzinga
10X Genomics stock price target raised to $22 from $20 at Canaccord Genuity - Investing.com UK
Why Is 10x Genomics (TXG) Stock Soaring Today - Finviz
10X Genomics stock price target raised to $22 from $20 at Canaccord Genuity By Investing.com - Investing.com India
10x Genomics (NASDAQ:TXG) Shares Gap Up on Earnings Beat - MarketBeat
10 X Genomics Inc Azioni (TXG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.39%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):